Business Wire

PSA-CERTIFIED

4.4.2024 10:01:28 CEST | Business Wire | Press release

Share
PSA Certified Announces New PSA Certified Level 4 Certification and Continued Partner Growth

PSA Certified, the global security and evaluation framework for the connected device ecosystem, has today announced its highest certification level to date as it accelerates its mission to build assurance in connected devices. The new PSA Certified Level 4 iSE/SE certification offers enhanced protection of high value assets that can secure valuable AI models, future-proofing systems against new attack methods and rising security threats linked to the rapid adoption of edge AI. Its launch follows a period of strong momentum for PSA Certified which has become a trusted route for demonstrating security best practice and the assurance of connected devices.

David Maidment, Senior Director, Secure Devices Ecosystem at Arm (a PSA Certified co-founder):

As the world embraces a new set of AI-enabled use cases, the value of data and assets has never been higher; nor has the importance of protecting them. The launch of PSA Certified Level 4 iSE/SE is testament to our commitment to helping the industry deploy security features that will protect devices and models from malicious changes and theft now, as well as over the next decade.”

As security cements its position as a business imperative, forward-looking companies are uplevelling their investment in security-by-design. PSA Certified has now surpassed the milestone of 200 certifications from nearly 90 technology providers, making it one of the most successful schemes to address connected device security.

The newly launched PSA Certified Level 4 Integrated Secure Enclave / Secure Element (iSE/SE) certification, already available at PSA Certified Labs, builds on the scheme’s momentum further and underpins a step change that can be used to protect valuable models and data during device boot and at rest (when models reside in secure storage). The level recognizes the use of a highly robust integrated Secure Enclave (iSE) or Secure Element (SE) - that acts as a trusted subsystem to the full Root of Trust (PSA RoT). By safeguarding critical cryptographic functions and key storage, OEMs can now ask for a RoT with a trusted subsystem that offers a ‘high’ level of attack resistance.

Benefits of PSA Certified Level 4 iSE / SE Certification include:

Protecting ML models at rest with highly robust crypto and key storage

  • PSA Certified Level 4 iSE/SE considers more sophisticated attack methods in scope. Chips that achieve this new level could be used in an AI context to help protect valuable models and data at boot and rest: some chips will need protection from advanced fault injection and differential power analysis (up to and including EMFI, single laser and multi-glitching). PSA Certified Level 4 iSE/SE chips will also benefit from stronger cryptography of at least 128-bit strength. The new level offers a “high” level of protection of the PSA-RoT assets from physical or software attack.
  • A trusted subsystem that achieves PSA Certified Level 4 iSE/SE can be used through composition in a PSA Certified Level 3+SE certification of the full PSA RoT security functionality. The PSA Certified Level 3 document has been updated to allow this new certification level.

PSA Certified Level 4 iSE/SE will help protect emerging use cases from sophisticated security attacks

  • PSA Certified Level 4 iSE/SE offers additional security against more advanced attacks. Chips that offer this RoT provide a strong trust anchor that could be used to decrypt and verify OTA updates which help protect models in high-value systems.
  • Industrial and safety-critical use cases need to support system recovery and stronger authentication: re-establishing integrity, confidentiality and availability are fundamental when rebooting systems and deploying OTA updates when faults are found, or upgrades are required. PSA Certified iSE/SE also mandates higher strength cryptography, which protects against more sophisticated attacks.
  • Trust anchor for Edge AI and infrastructure chips, providing a “High” level of protection against physical and software attacks on critical assets that require a more robust Root of Trust to maintain system integrity.

A transparent certification scheme with a route to High, Substantial, and Basic levels of robustness and assurance, purpose-built for the SoC market

  • PSA Certified offers a variety of robustness levels to match the market’s needs, all specifically designed for the electronics industry. By allowing a trusted subsystem to be certified as a component, and that certificate reused as part of a complete PSA RoT many times, chip vendors benefit from significant time and cost savings.

The first partner to aim for the PSA Certified Level 4 iSE/SE standard is Infineon, showcasing its commitment to developing IoT devices to the highest security-by-design standards.

Erik Wood, Senior Director, IoT Secure MCU Products at Infineon comments:

“In the age of AI, the risks of insecurity are immense and increasing. I’ve backed PSA Certified since launch and I am impressed by its success in uniting the technology ecosystem around the common goal of improving trust and security within the connected device ecosystem, while aligning to emerging government standards and legislation. The launch of PSA Certified Level 4 iSE/SE takes that one step further. With this new level, the electronics industry is better able to protect against the growing advancement of attack methods driven by the explosion of machine learning, generative AI and LLM.”

About PSA Certified

PSA Certified is a global partnership of security-conscious companies who are proactively building security best practices into devices at scale. Our security framework and independent third-party evaluation scheme was originally spearheaded by Arm and six other security ecosystem leaders (and now maintained by Applus+ Laboratories, CAICT, ECSEC Laboratory, ProvenRun, Riscure, SGS Brightsight, Serma, TrustCB, and UL) providing the resources needed to build upon the Root of Trust.

PSA Certified has scaled to become one of the fastest growing, most valued security ecosystems, globally. Being awarded ‘Ecosystem of the Year’ in the IoT Global Awards 2021 is testament to the role it has played in uniting industry, standards bodies, regulators and insurers together under one initiative. In doing so it’s accelerating the cross-industry collaboration required to untap the full potential of the IoT.

With 200 certifications from 88 partners, PSA Certified has democratized the adoption of security across the electronics industry, giving the ecosystem the confidence to innovate, while protecting consumers from the most common hacks.

Find out more: psacertified.org

1A Certified Security Report 2023

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240404517921/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents23.4.2026 13:29:00 CEST | Press release

Mangaciclanol, if approved, could transform contrast-enhanced MR imaging by offering an alternative to - or even replacing - gadolinium-based MRI agentsA manganese-based MRI contrast agent could address concerns with gadolinium-based contrast agents around retention in the body, security of supply, and the environment, with mangaciclanol’s clinical development under FDA Fast Track designationThe program demonstrates GE HealthCare’s commitment to advancing novel imaging agents to address unmet patient needs GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging (MRI) contrast agent, mangaciclanol, at Mayo Clinic in Rochester, Minnesota. Mangaciclanol, if approved, could offer an alternative to – or even replace – gadolinium-based MRI contrast agents, the current standard of care. The investigational agent has been granted Fast Track designation by t

Croma Pharma Launches AI-Driven Tech Venture to Revolutionize Aesthetic Medicine via Clinicore Platform23.4.2026 13:13:00 CEST | Press release

New structure to drive AI-powered innovation and international expansion Croma Pharma has launched a strategic joint venture to accelerate the development of Clinicore, its premium digital solution for aesthetic practices. This dedicated entity will focus on scaling the next generation of the platform while ensuring full continuity for existing users. Clinicore: Elevating Practice Excellence through AI Clinicore is a specialized SaaS (Software as a Service) solution designed to optimize the daily operations of aesthetic clinics. By automating patient management, scheduling, and administrative workflows, it enables healthcare professionals to focus entirely on patient care. A core element of the new strategy is a strong focus on Artificial Intelligence. Clinicore is evolving into a smart assistant, utilizing AI-driven features for automated treatment documentation, intelligent onboarding tools, and advanced process automation. This ensures that clinics can operate at maximum efficiency

NIQ Launches Commerce Lab to Build the Data and Measurement Layer for AI-Driven Commerce23.4.2026 13:00:00 CEST | Press release

NielsenIQ (NYSE: NIQ) today announced the launch of NIQ Commerce Lab, where the company is building the technology infrastructure for AI-driven commerce. The Lab will develop the data platforms, APIs, and measurement systems that power how products are discovered, evaluated, and purchased in AI-mediated environments. This includes what the industry often refers to as agentic commerce, but extends across quick commerce, social commerce, and other emerging channels—where AI is becoming the common layer shaping how consumers navigate choices and how decisions are made in real time. AI systems are rapidly moving from supporting decisions to making them—playing an increasingly central role in how commerce operates. Their effectiveness depends on the intelligence behind them. AI is Becoming the Operating Layer of Global Commerce NIQ ensures that the intelligence behind these systems is accurate, complete, and grounded in real-world behavior—reflecting how consumers actually buy, what product

Chiesi Reports Strong FY2025 Financial and Sustainability Results and Announces Leadership Transition Highlights23.4.2026 12:10:00 CEST | Press release

Strong FY2025 financial and sustainability results; leadership transition will support continuity and long-term growth Revenue up 8.2% to €3.6bn with double-digit growth in Rare Diseases and U.S. market Air sales at €1.886bn, growing 3.9% vs. 2024 - Care sales at €904m growing 13.3% vs. 2024 - Rare sales at €906m, growing 22.3% vs. 2024 Giuseppe Accogli leaving to pursue another opportunity, Group CFO Jean-Marc Bellemin named Interim CEO while new CEO search is underway Record €885m Research & Development (R&D) investment underscores continued commitment to innovation across respiratory, rare disease and specialty care Sustainability leadership further strengthened through B Corp recertification and progress on Carbon Minimal Inhaler (CMI) innovation Chiesi Group (“Chiesi”), an international research‑focused biopharmaceutical company and certified B Corp, today announced its financial results for the year ended 31 December 2025. Chiesi reported €3.625 billion in consolidated revenues,

REPLY S.p.A.: Shareholders’ Meeting Approves the 2025 Financial Statements23.4.2026 12:05:00 CEST | Press release

Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);Group net profits of €250.9 million (€211.1 million in 2024).Approval of the proposal to distribute a dividend of €1.35 per share.Approval of the plan for the purchase and/or disposal of treasury shares. The General Shareholders’ meeting of Reply S.p.A. [EXM, STAR: REY] held today approved the Financial Statements for the financial year 2025, confirming the distribution of a gross dividend of €1.35 per share. The dividend will be paid on 20 May 2026, with dividend date set on 18 May 2026 (record date on 19 May 2026). Approval of the 2025 financial statements The Reply Group closed the 2025 financial year with a consolidated turnover of €2,483.6 million, recording a 8.0% increase compared to €2,300.5 million in 2024. Consolidated EBITDA was €467.6 million, up 13.9% compared to €410.6 million recorded for the year 2024. EBIT, from January to December, was €397.1 million, up 18.5% compared to €330.4 million recorded for

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye